Literature DB >> 5316400

Individual differences in the plasma half-lives of lipid soluble drugs in man.

D S Davies, S S Thorgeirsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5316400     DOI： 10.1111/j.1600-0773.1971.tb03298.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN： 0001-6683


× No keyword cloud information.
  10 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Disposition and oxidative metabolism of phenylbutazone in man.

Authors:  J Aarbakke; O M Bakke; E J Milde; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

3.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

4.  Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol.

Authors:  S E Smith; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man.

Authors:  L F Gram; P B Andreasen; K F Overo; J Christiansen
Journal:  Psychopharmacology (Berl)       Date:  1976-10-20       Impact factor: 4.530

6.  Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man.

Authors:  S Loga; S Curry; M Lader
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

7.  Plasma concentration of phenylbutazone and its therapeutic effect-studies in patients with rheumatoid arthritis.

Authors:  M Orme; P J Holt; G R Hughes; C J Bulpitt; G H Draffan; S S Thorgeirsson; F Williams; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

8.  Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction?

Authors:  J L Cunningham; D A Evans
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

9.  m-Trifluoromethyl-alpha-ethylbenzhydrol: a new enzyme inducer.

Authors:  B Gachályi; A Káldor; S Szeberényi
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

10.  A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients.

Authors:  C Higham; L Aarons; P J Holt; M Lynch; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.